Advertisement

Glioma of the Central Nervous System Surveillance Counterpoint: Australia

  • Margot Lehman
  • Michael BartonEmail author
Chapter
Part of the Current Clinical Oncology book series (CCO)

Abstract

The median age at diagnosis of primary brain cancers in Australia was 55–59 years for males and 60–64 for females in 1999. Low-grade gliomas have a peak incidence in the fourth decade [1]. For high-grade gliomas the peak incidence occurs in the eighth decade. There were 1,369 people, or 6.8 per 100,000, diagnosed with primary brain cancer in 2004, the latest year for which national figures are available [2, 3]. In comparison, approximately 161 new cases of breast cancer and 64 new cases of colon cancer were diagnosed per 100,000 population that year. The Australian Institute of Health and Welfare ranks primary brain cancer as the 14th most common cancer. In the Australian States and Territories, the age-standardized incidence of brain cancer ranged from 6.3 per 100,000 in Western Australia and the Northern Territory to 7.5 per 100,000 in Victoria in 2001 (the most recent year for which State data are available) [4].

Keywords

Astrocytoma Glioblastoma multiforme Glioma Magnetic resonance imaging Positron emission tomography Pseudo-progression 

References

  1. 1.
    Surveillance, Epidemiology and End Results SEER Program. SEER*Stat Database: Incidence—SEER 9 Regs Public-Use, Nov 2003 Sub (1973–2001), 1 April 2004. National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.Google Scholar
  2. 2.
    AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries). Cancer in Australia: an overview, 2006, No. 37, Cancer series. Canberra: AIHW; 2007.Google Scholar
  3. 3.
    Australian Institute of Health and Welfare. ACIM (Australian Cancer Incidence and Mortality) Books. Canberra: Australian Institute of Health and Welfare; 2007.Google Scholar
  4. 4.
    Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer survival in Australia, 2001. Part 1: National summary statistics, 13. Cancer Series No. 18. Canberra: Australian Institute of Health and Welfare; 2001.Google Scholar
  5. 5.
    Australian Institute of Health and Welfare and Australasian Association of Cancer Registries. Cancer in Australia 2001, Cancer Series, vol. No. 28, CAN 23. Canberra: AIHW; 2004.Google Scholar
  6. 6.
    Access Economics. Cost of cancer in NSW, 15 June 2006. Sydney: Cancer Council NSW.Google Scholar
  7. 7.
    Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002;61:215.PubMedGoogle Scholar
  8. 8.
    Rosenthal MA, Drummond KJ, Dally M, Murphy M, Cher L, Ashley D, et al. Management of glioma in Victoria (1998–2000): retrospective cohort study. Med J Aust. 2006;184:270–3.PubMedGoogle Scholar
  9. 9.
    Chang SM, Parney IF, Huang W, Anderson FA, Asher AL, Bernstein M, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293(5):557–64. Am Med Assoc. Ref Type: Generic.PubMedCrossRefGoogle Scholar
  10. 10.
    Frappaz D, Chinot O, Bataillard A, Ben HM, Capelle L, Chanalet S, et al. Standards, options and recommendations 2002 for the management of adult patients with intracranial gliomas (summary report). Bull Cancer. 2003;90:873–86.PubMedGoogle Scholar
  11. 11.
    Australian Transport Council. Assessing fitness to drive for commercial and private vehicle drivers, and clinical management guidelines, vol. 3. Sydney: Austroads; 2003.Google Scholar
  12. 12.
    Chiro GD, Brooks A, Kornblith PL, Smith H. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol. 1984;15:S138–46.PubMedCrossRefGoogle Scholar
  13. 13.
    Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med. 2005;352:987–96.PubMedCrossRefGoogle Scholar
  14. 14.
    Mason WP, Del Maestro R, Eisenstat D, Forsyth P, Fulton D, LaperriFre N, et al. Canadian recommendations for the treatment of glioblastoma multiforme. Curr Oncol. 2007;14:110.PubMedCrossRefGoogle Scholar
  15. 15.
    Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995;345:1008–12.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press 2013

Authors and Affiliations

  1. 1.Princess Alexandra HospitalWoolloongabbo, QLDAustralia
  2. 2.Liverpool Cancer Therapy CentreLiverpool, BCAustralia

Personalised recommendations